Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Global Human Hair Wigs and Extensions Market Poised to Reach USD 9.3 Billion by…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=145496 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Human Hair Wigs and Extensions Market Overview Geographic Dominance : Geographically,North Americadominates the Human Hair Wigs and Extensions market, withthe United Statesbeing the largest consumer. The region's...
PR Newswire
07/11/2024
Global HLA Typing for Transplant Market to Reach USD 2.1 Billion by 2031, Driven…
Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014873 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=1014873 202 - Pages 126 – Tables 37 – Figures Scope Of The Report HLA Typing For Transplant Market Overview 1. Market Size and Growth Projections The global HLA Typing for Transplant Market is anticipated to grow steadily from 2024 to 2031, with a projected increase fromUSD 1...
PR Newswire
07/11/2024
With CAGR of 8.6%, Poultry Vaccine Market Size to Reach $4.1 Billion By 2031 |…
Read full market research report, "Poultry Vaccines Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Broiler and Layer), Technology (Live Attenuated Vaccines, Inactivated Vaccines, and Recombinant Vaccines), Dosage Form (Liquid Vaccines, Freeze-Dried Vaccines, and Dust/Powder Form Vaccines), Disease [Avian Influenza, Avian Salmonellosis, Marek's Disease, Infectious Bronchitis, Infectious Bursal Disease (IBD)…
PR Newswire
07/11/2024
Periodontal Disease Treatment Market to Hit USD 3.63 Billion by 2030 with 5.9%…
Browse in-depth TOC on "Periodontal Disease Treatment Market" Browse in-depth TOC on "Periodontal Disease Treatment Market" 300 - Tables 60 - Figures320 - Pages In the European region, the legal system involving drugs is the European Medicines Agency (EMA) and devices under the Medical Device Regulation (MDR). The EMA has been careful in ensuring that drugs on periodontal conditions are tested not only for their benefits but also for their risks. In contrast, the MDR has…
PR Newswire
07/11/2024
Women Health App Market Surges to USD 8 Billion by 2030, Propelled by 14.4% CAGR…
Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=216134 Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=216134 Browse in-depth TOC on Women Health App Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Women Health App Market Overview Market Drivers Fueling Growth in the Women Health App Market To Purchase a Comprehensive Report Analysis: ...
PR Newswire
07/11/2024
Next-Generation Sequencing (NGS) Services Market is expected to generate a…
As precision medicine and genomics revolutionize healthcare, the demand for NGS services has surged, driven by advancements in diagnostics, personalized treatment plans, and biopharmaceutical R&D. This report is essential for professionals in life sciences, biotechnology, and clinical research looking to capitalize on the transformative potential of NGS services. As precision medicine and genomics revolutionize healthcare, the demand for NGS services has surged, driven by advancements in...
PR Newswire
07/11/2024
Immunovia presents data from model development study at meeting of the PRECEDE…
The annual meeting of the PRECEDE Consortium will bring together pancreatic cancer experts for two days of informational panels, partner updates, collaboration, and information sharing. Founded in 2020, the international PRECEDE Study is open to individuals with a family history of pancreatic cancer and/or those who carry genetic variants linked to development of the cancer. The PRECEDE Consortium's ambitious goal is to increase the five-year survival rate to 50% within the next 10 years through…
PR Newswire
07/11/2024
The Accumulus Platform Powers Sanofi's Submissions to Multiple Regulators Around…
“The Accumulus platform introduces unprecedented scalability and is designed to unlock the full potential of reliance pathways and regulatory collaboration as a whole,” said Francisco Nogueira, CEO at Accumulus. “We're offering a solution that helps shorten cycle times, accelerate review and feedback, and increase equitable patient access on a global scale. We're not just making reliance pathways viable—we're making them scalable and operational.”Sanofi's adoption of the Accumulus platform...
Nasdaq GlobeNewswire
07/11/2024
Promising cooperation between medac and chiron for the development of organ-on…
Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further development and establishment of animal free testing methods for the pharmaceutical industry. Animal testing still has a role for medical research and the development of therapies. Due to legal requirements...
Nasdaq GlobeNewswire
07/11/2024
Cancer Genetic Risk Assessment Guidelines Expand to Meet Growing Understanding…
Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment. Additional cancer types were added to the title and content for both guidelines. These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment. "These expanded guidelines reflect the recommendations from leading experts on genetic testing based on the…
PR Newswire
07/11/2024
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and…
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi's 2024 Global Healthcare Conference in Miami, Florida on December 4, 2024, and in Evercore's HealthCONx Conference in Coral Gables, Florida on December 5, 2024. Members of the management team will host one-on-one meetings at both conferences. Alvotech will also hold a fire-side chat at Evercore's HealthCONx...
Nasdaq GlobeNewswire
07/11/2024
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III…
AV001 is a randomized, double-blind 42-week trial including 410 patients who have been suffering from moderate to severe PSNP for at least six months. The primary endpoint of the trial is a reduction in the average pain intensity after 12 weeks compared to baseline. In addition, the trial assesses other outcomes including reduction in the average pain intensity after 42-weeks, progressive response over time with repeated treatment, reduction of the treatment area over several applications, and…
PR Newswire
07/11/2024
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
Guggenheim's Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MAJefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in LondonCiti's 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FLEvercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL Live webcasts and archived replays of the...
Nasdaq GlobeNewswire
07/11/2024
Tilray Medical Announces Positive Results from Study on Oral Cannabis Extract…
Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)." This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 mg of THC and 2.5 mg of CBD or a placebo, taken three times daily for six days.From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract...
Nasdaq GlobeNewswire
07/11/2024
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and…
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimab...
Nasdaq GlobeNewswire
07/11/2024
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall…
DUBLIN, Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia, at two scientific conferences this fall. The two meetings—the 37th Annual Psych Congress (Psych Congress), which took place…
PR Newswire
07/11/2024
MGI Tech Partners with the Human Cell Atlas to Further Advance Worldwide Human…
Under this partnership, HCA members will enjoy more access to MGI's cost-effective and scalable single cell and spatial omics solutions. In addition, MGI will also provide support to members in experimental design, assay execution, and bioinformatic support when applying MGI's technologies to their research. Under this partnership, HCA members will enjoy more access to MGI's cost-effective and scalable single cell and spatial omics solutions. In addition, MGI will also provide support to...
PR Newswire
07/11/2024
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
Significant advancement on product portfolio, including enrollment in the OCS-01 DIAMOND Phase 3 program in DME and OCS-05 Phase 2 ACUITY trial in acute optic neuritis (AON) with topline readout anticipated in December 2024Leadership team bolstered with extensive experience in key areas as the Company advances its late-stage pipeline and prepares for commercial phaseCash, cash equivalents and short-term investments of $125.0 million as of September 30, 2024, provides cash runway into...
Nasdaq GlobeNewswire
07/11/2024
NAYO to Announce the Launch of Fully Automated Biobanking Solutions in Europe at…
Chandler Luo, Chief Executive Officer of NAYO, said, "This exhibition is a fantastic platform for showcasing NAYO's liquid handlers and powerful innovation technology to a global audience. We hope to engage in meaningful discussions on cooperation with partners and leading medical institutions worldwide. By leveraging the flexible-based-platform, we aim to maximize resource utilization, foster close collaborations with medical professionals globally." Chandler Luo, Chief Executive…
PR Newswire
07/11/2024
LG UNVEILS "PROFESSIONAL LAUNDRY" LINEUP FOR COMMERCIAL MARKET AT TEXCARE 2024
LG's comprehensive range of large-capacity commercial washers and dryers provides several outstanding options for customers to choose from. The new PROFESSIONAL LAUNDRY lineup features 20-, 25- and 30-kilogram washers, as well as 25- and 30-kilogram dryers, along with a 25- kilogram washer-dryer combo. These solutions are equipped with LG's advanced AI technology, which automatically adjusts water usage and washing/drying times based on load size, enabling a complete cycle in just 60 minutes.*…
PR Newswire
07/11/2024
Serres Receives €1.8 Million Research Grant from Business Finland
"The project supports the company's strategic renewal, positioning it as a leader in sustainable development by providing solutions for collecting hospital patient fluids and plastic waste. This highly ambitious research project combines various aspects within its work packages to achieve the desired results. Business Finland's funding allows for implementing a large-scale project that improves international business prospects", states Eija-Riitta Hämäläinen at Business Finland…
PR Newswire
07/11/2024
Enzymatica AB's Interim report Q3/2024: Focus on developing existing and new…
"The two highest priorities on the company's agenda are accelerated sales in existing markets and partner agreements for new markets. Accordingly, we are strengthening our sales organization and planning to revamp our marketing strategy as well. The MDR certification we received last spring allows us to make new and stronger health claims. Over the past few weeks, the new MDR-labeled packages have started to appear on pharmacy shelves in Sweden, and new campaigns will soon follow. "The…
PR Newswire
07/11/2024
Q3 update: Novonesis delivers strong Q3 results and now expects full-year…
Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong performance has led Novonesis to now expect full-year organic sales growth to be at the upper end of the 7-8% range, and the adjusted EBITDA margin is confirmed to be between 35.5-36.5%.COPENHAGEN, Denmark – November 7, 2024.Novonesis delivers 9% organic sales growth, in the first nine months...
Nasdaq GlobeNewswire
07/11/2024
Trading statement 9M 2024
Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin confirmed between 35.5-36.5%.Ester Baiget, President & CEO: “We continue to execute strongly across the business. Supportive, broad-based demand coupled with strong innovation and commercial focus drive higher market penetration. Novonesis' biosolutions are increasingly requested by customers to...
Nasdaq GlobeNewswire
07/11/2024
Altri Comunicati
